Mike Gait News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PepGen Raises $108 Million in IPO to Advance Neuromuscular Disease Pipeline

PepGen Raises $108 Million in IPO to Advance Neuromuscular Disease Pipeline
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United kingdomMatthew woodLaboratory of molecular biology in cambridgeUniversity of oxfordNasdaq global select marketMike gaitMolecular biologyEnhanced delivery oligonucleotide

PepGen IPO nabs $108M for muscular dystrophy drug with potential edge over Sarepta med

PepGen’s technology improves the delivery of a therapy to more tissue types and the clinical-stage biotech plans to use its IPO cash to continue developing its lead program for Duchenne muscular dystrophy. Meanwhile, eye products giant Bausch + Lomb returned to the public markets as a standalone company. Both the PepGen and Bausch + Lomb IPOs priced below their respective price ranges.

United kingdomJoe papaMatthew woodYork stock exchangeOxford sciences enterprisesUniversity of oxfordToronto stock exchangeBausch health companiesResearch council of united kingdomNew york stock exchangeValeant pharmaceuticalsOxford universityBausch healthMassachusetts based pepgenNasdaq fridaySarepta therapeutics